BlackDoctor.org, a health platform that reaches 20 million people, launched a new initiative, Generational Health, that aims ...

Square Pharmaceuticals, the country's leading drug manufacturer, reported a 15% rise in consolidated net profit to Tk2,397 crore for FY25, driven by strong performances from its subsidiaries and ...

November 3, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, announced ...

All data from 1,100+ Answer ALS participants, including ALS TDI's ARC study data, are now harmonized and accessible via the Neuromine Data Portal, forming ...

GC Biopharma, a leading global pharmaceutical company based in South Korea, announced today that the Phase 2 clinical trial results for its anthrax vaccine 'BARYTHRAX inj. (GC1109)' have been ...

SSA confirmed a 2.8% COLA for 2026. Learn when checks hit, how taxes and Medicare may change, and the smart moves to keep ...

November 3, 2025 Biodexa Announces Approval of CTA in Europe for Phase 3 Serenta Trial in FAP First European patient expected to be enrolled in 4Q 2025 Addressable US - European Market Put at $7 Billi ...

Biodexa Announces Approval of CTA in Europe for Phase 3 Serenta Trial in FAP. First European patient expected to be enrolled in 4Q 2025. Addressable US - Europea ...

Lumen Biosciences Brian Finrow breaks down Chinas biotech playbook and explores ways the U.S. can adapt it for its own continued success.

Servier today announced longer-term data from the Phase 3 INDIGO trial evaluating VORANIGO® (vorasidenib) versus placebo in patients with Grade 2 mutant isocitrate dehydrogenase 1 or 2 (mIDH1/2) ...

The boy from Geelong grew up in a pub, studied to be a chemist, sold IBMs and opened his first restaurant at 35. Now he’s one ...

There is no evidence that less frequent financial reporting impairs company performance, market functioning, or the quality of investor information.